Hydrogels includes dressings that consist of 96% water with a matrix of insoluble polymers embedded in it. The former helps to maintain a moist wound environment while the latter facilitates absorption of wound exudates.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Hydrogels under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hydrogels and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to :
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Hydrogels under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3QMatrix, Inc. (Inactive)
- Abeona Therapeutics Inc
- Alafair Biosciences Inc
- Albert Ludwigs University of Freiburg
- Amend Surgical, Inc.
- Angiotech Pharmaceuticals Inc
- AXXO Im- und Export GmbH
- BioCure Inc
- Biomendics LLC
- Brigham and Women's Hospital
- CelaCare Technologies LLC
- Ceramicos Para Aplicacoes Medicas SA
- Chi2Gel Ltd.
- Clyra Medical Technologies Inc
- CorMedix Inc
- Drexel University
- ECM Therapeutics Inc
- Edixomed Ltd
- Exogenus Therapeutics SA
- Flexion Therapeutics Inc
- Gel4Med Inc
- Gelesis Inc
- GelSana Therapeutics Inc
- HyperBranch Medical Technology Inc
- Icahn School of Medicine at Mount Sinai
- In2cure AB
- Indian Institute of Technology Delhi
- Indian Institute of Technology, Kanpur
- Institute of Nano Science and Technology
- Ionic Pharmaceuticals LLC
- IPI Singapore
- Jenarron Therapeutics Ltd
- Johns Hopkins University
- Kane Biotech Inc
- Keratin Biosciences Inc
- Magle Chemoswed AB
- McMaster University
- Missouri University of Science and Technology
- Neotherix Ltd
- Northwestern University
- Novyx Technologies LLC
- O2 Regentech LLC
- Ohio State University
- Orla Protein Technologies Ltd
- Piramal Enterprises Ltd
- Plurogen Therapeutics Inc (Inactive)
- Queensland University of Technology
- Quick-Med Technologies Inc
- Quthero Inc
- Regentys Corp
- Scarless Laboratories Inc
- Serina Therapeutics Inc
- SolasCure Ltd
- Sonoma Pharmaceuticals Inc
- Spanish National Research Council
- Squid Healthcare Inc
- Stanford University
- Sunogel Biotechnologies Inc
- SynDermix AG
- Syracuse Biolabs Inc
- Syracuse University
- Tectum
- Tel Aviv Sourasky Medical Center
- Tel Aviv University
- Texas Medical Center
- Tokyo University of Science
- University of California San Diego
- University of Florida
- University of Illinois at Chicago
- University of Pennsylvania
- University of Queensland
- University of Wisconsin Madison
- Ventrix Inc
- VTT Technical Research Centre of Finland Ltd
- Washington University in St Louis
- Zeomedix, LLC

